Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SIBP-04 (bevacizumab biosimilar)
i
Other names:
SIBP-04, SIBP 04, SIBP-A04
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Sinopharm
Drug class:
VEGF-A inhibitor, Angiogenesis inhibitor
Related drugs:
‹
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
bevacizumab-nwgd (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
BNT327 (2)
CTX-009 (1)
BP102 (bevacizumab biosimilar) (0)
SCT510 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
ranibizumab (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
SJ-C1044 (2)
VB-111 (2)
E7050 (1)
CM101 (0)
defibrotide (0)
squalamine (0)
ADH-1 (0)
GS-156 (0)
TL-118 (0)
84AA-API 14AA (0)
RC402 (0)
IOA-289 (0)
ENV-105 (0)
iMX-110 (0)
ACE-041 (0)
sonepcizumab (0)
PT-112 (0)
PG545 (0)
L19-I131 (0)
rifampicin (0)
LB401 (0)
SU5416 (0)
CB1089 (0)
ABT-510 (0)
bevacizumab (416)
Aybintio (bevacizumab biosimilar) (14)
bevacizumab-maly (12)
bevacizumab-awwb (11)
bevacizumab-adcd (11)
bevacizumab-tnjn (8)
bevacizumab-bvzr (8)
bevacizumab-nwgd (7)
Byvasda (bevacizumab biosimilar) (4)
ziv-aflibercept IV (4)
BNT327 (2)
CTX-009 (1)
BP102 (bevacizumab biosimilar) (0)
SCT510 (bevacizumab biosimilar) (0)
Ankada (bevacizumab biosimilar) (0)
BI 695502 (bevacizumab biosimilar) (0)
MIL 60 (bevacizumab biosimilar) (0)
LY01008 (bevacizumab biosimilar) (0)
CBT124 (bevacizumab biosimilar) (0)
Cizumab (bevacizumab biosimilar) (0)
Equidacent (bevacizumab biosimilar) (0)
GB222 (bevacizumab biosimilar) (0)
GZ402663 (0)
HLX-04 (bevacizumab biosimilar) (0)
LYN-00101 (0)
ranibizumab (0)
MP0250 (0)
MSB0254 (0)
Onbevzi (bevacizumab biosimilar) (0)
PB101 (0)
Pusintin (bevacizumab biosimilar) (0)
TRS003 (bevacizumab biosimilar) (0)
HD204 (bevacizumab biosimilar) (0)
bevacizumab biosimilar (0)
hVEGF26–104/RFASE (0)
APX003 (0)
SJ-C1044 (2)
VB-111 (2)
E7050 (1)
CM101 (0)
defibrotide (0)
squalamine (0)
ADH-1 (0)
GS-156 (0)
TL-118 (0)
84AA-API 14AA (0)
RC402 (0)
IOA-289 (0)
ENV-105 (0)
iMX-110 (0)
ACE-041 (0)
sonepcizumab (0)
PT-112 (0)
PG545 (0)
L19-I131 (0)
rifampicin (0)
LB401 (0)
SU5416 (0)
CB1089 (0)
ABT-510 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
SIBP-04 (bevacizumab biosimilar)
Sensitive: B - Late Trials
SIBP-04 (bevacizumab biosimilar)
Sensitive
:
B
SIBP-04 (bevacizumab biosimilar)
Sensitive: B - Late Trials
SIBP-04 (bevacizumab biosimilar)
Sensitive
:
B
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.